Physician profile
Sumit Kapoor
NPI 1376777433
$12,423.93
in general payments reported to CMS, 2019-2025
14 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,860 · 2020: $1,890 · 2021: $95.91 · 2022: $120 · 2023: $971 · 2024: $364 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127 · Travel and Lodging: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.04 |
| Travel and Lodging | $331.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10,547.77 | 2019-2020 | |
| Boston Scientific Corporation | $505.39 | 2023 | Resolution 360 Ultra Clip, Resolution 360 Clip |
| Medtronic, INC. | $299.33 | 2021-2024 | Gi Genius |
| Abbvie INC. | $209.90 | 2019-2025 | |
| Genzyme Corporation | $202.70 | 2022-2024 | |
| Echosens North America, INC. | $143.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $139.99 | 2019-2023 | Rebyota |
| Qol Medical, LLC | $135.45 | 2023 | Sucraid |
| Novo Nordisk INC | $121.36 | 2024 | Wegovy |
| Phathom Pharmaceuticals, INC. | $35.05 | 2024 | Voquezna |
| Janssen Biotech, INC. | $23.35 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $23.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.31 | 2024 | Entyvio |
| Celltrion USA INC. | $18.20 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.